30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Biomatlante's MBCP Matrix Selected for Fracture Study -

MBCP+™, Biomatlante's synthetic bone graft matrix, has been confirmed as the adapted matrix of choice for tissue engineering and was selected for use in a 5-year trial in the treatment of long bone nonunions. The ORTHOUNION randomized clinical trial will compare a combination of MBCP+ and expanded bone marrow mesenchymal stem cells (MSCs) to autograft in the treatment of long bone nonunions. (Biomatlante, 2/28/18)